20/20 BioLabs, Inc. (NASDAQ: AIDX) shares listed slightly lower Friday. The Gaithersburg, Md.-based company, an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that 18 groups of Maryland fire departments have been notified that they will collectively be awarded over $520,000 from the Maryland Department of Health (MDH) to procure and administer the Company’s patented OneTest™ multi-cancer early detection (MCED) blood test.
The funding is from the state’s Professional and Volunteer Firefighter Innovative Cancer Screening Technologies Grant Program, administered by MDH. The testing of these firefighters, estimated to exceed 1,400 individuals, is expected to take place in April or May of this year and represents a ~ 225% increase in the number of OneTest MCEDs funded through the same program last year.
“The Salisbury Fire Department has been very satisfied with the OneTest cancer screening products,” said Deputy Chief Truitt of the Salisbury MD Fire Department. “Over the past three years, these tests have enabled us to carry out almost 300 screenings. With a simple blood draw conducted by our Mobile Integrated Health team and paramedics, our members receive timely results that allow them to pursue any necessary follow-up care.”
AIDX shares dished off three cents, or 1.7%, to $1.70.
